Search This Blog

Monday, February 28, 2022

Glaxo: Daprodustat Drug Gets EU Marketing Authorization

 GlaxoSmithKline PLC said Tuesday that its drug Daprodustat has received marketing authorization by the European Medicines Agency.

The company said its application was accepted for review by the EMA.

The drug Daprodustat, aimed at treating anaemia of chronic kidney disease, is currently approved in Japan, the FTSE 100-listed company said.

https://www.marketscreener.com/quote/stock/GLAXOSMITHKLINE-PLC-9590199/news/GlaxoSmithKline-Says-Daprodustat-Drug-Gets-EU-Marketing-Authorization-39619011/

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)